New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?
Fiche publication
Date publication
novembre 2020
Journal
Current opinion in pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G
Lien Pubmed
Résumé
Over the past twenty years several biological drugs and the first small molecule have been approved for the treatment of patients with inflammatory bowel diseases (IBD). However, a large percentage of patients do not respond to therapies and the demand for new effective drugs is still an unmet need. The better understanding of the pathophysiological mechanisms of disease has allowed to identify new therapeutic targets to block inflammatory pathways. To date, many emerging drugs have been developed and are being tested for both ulcerative colitis and Crohn's disease patients. Here, we summarize the efficacy and safety data of the most promising drugs that could soon enrich the therapeutic armamentarium of IBD patients.
Référence
Curr Opin Pharmacol. 2020 Nov 27;55:141-150